NewGenIvf Registers $100 Million Financing Ceiling in Shelf Filing
Key Facts
NewGenIvf Group Limited filed an amendment to its Form F-3 registration statement with the U.S. Securities and Exchange Commission on November 9, 2026, allowing it to offer securities with an aggregate value of up to $100 million through one or more offerings over time. The SEC issued a notice that the registration became effective on November 12 at 4:30 p.m., providing the legal framework for offerings the company may conduct later. The registration does not mean the company has sold securities or raised proceeds in that amount; it sets an aggregate ceiling for potential instruments. The company said in the prospectus that it will present the specific terms of any issuance in a later prospectus supplement. Future supplements will also explain how the company will allocate proceeds from any sale it receives.
The instruments the company may offer include Class A ordinary shares and preferred shares, as well as warrants, debt securities, subscription rights and units. This range gives the company several options for structuring any financing, but the prospectus does not specify which instrument it will choose for a particular issuance. Issuing new shares could increase the number of shares outstanding and dilute existing shareholders, while the effects of any other instruments will depend on terms the company has not yet disclosed. The prospectus said: "We will provide the specific terms of any securities offered and any offering in a supplement to this prospectus." Details such as price, quantity and form of consideration will therefore become clear if an actual offering is announced. As for the use of proceeds, the company said their specific allocation will be stated in the relevant offering supplement.
The F-3 registration limits the size of public offerings while the market value of the outstanding Class A shares held by non-affiliates remains below $75 million. The prospectus states, based on the rule cited in it, that while the value remains below that threshold, such offerings may not exceed one-third of the aggregate market value of those shares during any 12-month period. The company estimated the value of shares held by non-affiliates at approximately $0.71 million, based on 1,550,309 shares and a closing price of $0.456 per share on November 6, 2026. These figures highlight the difference between the $100 million registration ceiling and the limit that may apply to public offerings under the circumstances specified in the prospectus. That limit remains tied to the market value of the public float and the specified period, rather than the registered ceiling alone. The prospectus presents the restriction as a condition on offering size over a 12-month period.
The capital figures in the prospectus show that the company had 1,589,083 Class A ordinary shares and 9,136 Class B ordinary shares outstanding, and no preferred shares outstanding, as of the prospectus date. These figures provide a view of the share base that could change if the company chooses to issue shares under the registration, while the terms of any future issuance remain unspecified. NewGenIvf describes itself as a holding company incorporated in the British Virgin Islands, and says its operations are conducted through subsidiaries in the Cayman Islands, the British Virgin Islands, the United States and Asia. This structure places the holding company at the center of the registration, while operating activities extend across those subsidiaries. Details of any financing and its use remain subject to an offering supplement the company may issue.
In its latest available semiannual financial disclosure, NewGenIvf reported revenue of $1,924,881 for the six months ended June 30, 2026, compared with $2,019,628 in the corresponding period of 2025. Revenue from fertility treatments totaled $1,574,320 in the first half of 2026, compared with $2,019,628 a year earlier. The company swung to a net loss of $8,079,392 in the first half of 2026, after recording net income of $698,032 in the first half of 2025. The company attributed $3,421,643 of the loss to a one-time loss related to a repurchase and forbearance agreement with JAK Opportunities VI LLC. The results provide financial context for the decision to register multiple financing instruments, but do not specify how the company would use any future proceeds. The company closed a public offering on September 30, 2026, that generated approximately $1.25 million in gross proceeds before fees and expenses.
NIVF shares closed at $0.2312 in the November 13, 2026 session, according to EL7 data. That followed the company’s use of a different closing price, $0.456, on November 6 to calculate the market value of shares held by non-affiliates; that was the prospectus reference date. The company also disclosed a one-for-eight reverse stock split, which took effect on October 23, 2026. These developments put recent share-price movements in the context of successive capital changes and financing disclosures, without by themselves determining the registration’s effect on trading. The prospectus does not provide terms or a date for a specific issuance; the company said any terms and allocation of proceeds will appear in the relevant supplements. The next financing-related development depends on the company announcing a supplement covering a particular offering.